Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated February 6, 2026, reports a significant regulatory milestone. The European Commission has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils. This approval expands Nucala's indications in Europe to include COPD alongside severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome.
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory announcement regarding product approval rather than a financial results report.
Material Changes and Clinical Data
The approval is based on the positive results of the MATINEE Phase III trial, which demonstrated statistically significant clinical benefits:
- Exacerbation Reduction: Nucala reduced the annualized rate of moderate/severe exacerbations by 21% compared to placebo (Rate Ratio 0.79; 95% CI 0.66, 0.94; P=0.01). The annualized exacerbation rate was 0.80 for Nucala versus 1.01 for placebo.
- Hospitalization Reduction: In a pre-defined secondary endpoint, the rate of exacerbations leading to emergency department visits or hospitalizations was reduced by 35% (Rate Ratio 0.65; 95% CI 0.43, 0.96). The annualized rate was 0.13 for Nucala versus 0.20 for placebo.
- Safety Profile: The incidence of adverse events was similar between the Nucala group (74%) and the placebo group (77%).
- Market Position: Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype.
Outlook, Management Commentary, and Risks
Management Commentary: Kaivan Khavandi, SVP of Global Head, Respiratory, Immunology & Inflammation R&D, stated that this approval offers the first monthly biologic option in the EU for adults with uncontrolled COPD and raised eosinophils, potentially reducing irreversible lung damage and hospitalizations.
Outlook: GSK aims to redefine the future of respiratory medicine by modifying underlying disease dysfunction. The company notes that COPD affects over 390 million people globally and is projected to be the leading cause of hospital admissions over the next decade.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks described in GSK's Annual Report on Form 20-F for 2024 and Q4 Results for 2025.
Key Facts for Investor Verification
- Verify the commercial launch timeline and pricing strategy for Nucala in the EU COPD indication.
- Assess the size of the addressable patient population in Europe with eosinophilic COPD not controlled by triple therapy.
- Review the competitive landscape for biologics in COPD, noting Nucala's status as the first monthly biologic with this specific Phase III data in the EU.
- Monitor upcoming financial reports for the impact of this new indication on respiratory segment revenue growth.
- Confirm the status of Nucala approvals in other major markets (US, UK, China) for COPD, which are already granted, to gauge global commercial momentum.